European Journal of Cancer
Volume 45, Issue 17 , Pages 2984-2991, November 2009

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

  • Matti Aapro

      Affiliations

    • Institut Multidisciplinaire d’Oncologie, Clinique de Genolier, CH-1272 Genolier, Switzerland
    • Corresponding Author InformationCorresponding author: Tel.: +41 (22) 366 91 06; fax: +41 (22) 366 91 31.
    • ,
  • Agustí Barnadas

      Affiliations

    • Hospital de Sant Pau, Barcelona, Spain
    • ,
  • Robert C. Leonard

      Affiliations

    • Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, UK
    • ,
  • Maurizio Marangolo

      Affiliations

    • Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy
    • ,
  • Michael Untch

      Affiliations

    • Helios Klinikum, Berlin Buch, Germany
    • ,
  • Lidia Ukarma

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland
    • ,
  • Hans-Ulrich Burger

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland
    • ,
  • Armin Scherhag

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland
    • I. Medical Clinic, University Hospital Mannheim, University of Heidelberg, Germany
    • ,
  • Bruno Osterwalder

      Affiliations

    • Hoffmann-La Roche Ltd., Basel, Switzerland

Received 18 September 2008; received in revised form 5 June 2009; accepted 26 June 2009. published online 31 July 2009.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    • PII: S0959-8049(09)00512-7

    doi:10.1016/j.ejca.2009.06.031

    European Journal of Cancer
    Volume 45, Issue 17 , Pages 2984-2991, November 2009